0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > VEGF: Cutting off tumor's feeding channel

VEGF: Cutting off tumor's feeding channel

VEGF: Cutting off tumor's feeding channel
Background

Not only vascular endothelial growth factor (VEGF) plays a role in promoting angiogenesis and regeneration, but shows multiple functions such as immune regulation and neuroprotection. VEGF family members exert their effects through interactions with a family of three VEGF receptors. VEGF is up-regulated when it overexpressed in many tumors. Therefore, it becomes a hot target of drug development for tumors.

Currently, there are more than 100 antibody drugs, such as monoclonal antibodies (mAb) and bispecific antibodies (BsAb) against VEGF are widely-used for clinical treatment.

Given its significant role in multiple cancer types, including tumors, intraocular neovascular disorders and other cardiovascular diseases, there is no surprise that VEGF has been heavily studied for new target therapeutics.

ACROBiosystems has developed a variety of VEGF proteins with different molecules, subtypes, species, and tags to help expedite your antibody drug development. All SPR&BLI protocols are available for free.

Product list
MoleculeCat. No.SpeciesProduct DescriptionStructure

>>>If you have any questions, suggestions or comments about VEGF, please contact us.

>>> Click here to find out more hot targets for bispecific antibodies.

Product Features
High purity verified by MALS

The purity of ActiveMax® Human VEGF165, Tag Free (MALS verified) (Cat. No.  VE5-H4210) was more than 95% in HP-SEC, and the molecular weight of this protein is around 40-55 kDa verified by SEC-MALS.

High bioactivity validated by ELISA&SPR&BLI&cell based assay
>>ELISA

Immobilized Human VEGF R3, Fc Tag (Cat. No.  FL4-H5251) at 5 μg/mL (100 μL/well) can bind Human VEGF-C, His Tag (Cat. No. VEC-H4225) with a linear range of 2-20 ng/mL (QC tested).

>>SPR

Immobilized Biotinylated Human VEGF165, His,Avitag (Cat. No. VE5-H82Q0) on CM5 Chip via Streptavidin, can bind Avastin with an affinity constant of 0.417 nM as determined in SPR assay (Biacore T200) (Routinely tested).

>>BLI

Loaded Avastin (Bevacizumab) on AHC Biosensor, can bind Human VEGF165, His Tag (Cat. No. VE5-H5248) with an affinity constant of 0.448 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

>>Cell based assay

ActiveMax® Human VEGF165, Tag Free (MALS verified) (Cat. No. VE5-H4210) stimulates proliferation of human umbilical vein endothelial cells (HUVEC). The ED50 for this effect is 4.216-9.281 ng/mL (Routinely tested).

Inhibition assay shows that the proliferation effect of ActiveMax® Human VEGF165, Tag Free (MALS verified) (Cat. No. VE5-H4210) is inhibited by increasing concentration of anti-VEGF mAb (Avastin). The concentration of VEGF165 used is 20 ng/mL. The ED50 is 0.065-0.229 μg/mL (Routinely tested).

Citations

This web search service is supported by Google Inc.

totop